Trials / Completed
CompletedNCT00272701
Esomeprazole in PPI Failures - IMPROVE
A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation of esomeprazole 40 mg compared to pre-study PPI treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole | |
| DRUG | Other PPI marketed in Sweden |
Timeline
- Start date
- 2005-12-01
- Completion
- 2007-02-01
- First posted
- 2006-01-09
- Last updated
- 2009-03-06
Locations
42 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00272701. Inclusion in this directory is not an endorsement.